Sanofi Pasteur and MSD have announced the end of their European vaccines joint venture so that their own “distinct growth strategies” can be pursued instead. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sanofi,_msd_to_dismantle_vaccines_jv_1020306AstraZeneca has bumped up its stake in US biotech Moderna, which is pioneering the development of a new class of drugs made of messenger RNA, to nine percent. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_ups_stake_in_moderna_1095937European regulators have accepted Sandoz’ marketing application for a biosimilar of Pfizer’s $9-billion-a-year anti-inflammatory Enbrel, the world’s fifth biggest selling drug. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sandoz_files_enbrel_biosimilar_in_the_eu_972256Sunovion’s application to market dasotraline for the treatment of attention-deficit hyperactivity disorder (ADHD) has been rejected by US regulators. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/fda_rejects_sunovions_adhd_drug_1251093UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/mallinckrodt_to_split_business_1272150AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_completes_acquisition_of_zs_pharma_972294Shire’s Board has notified Takeda that it would be “willing to recommend" the latter’s latest merger proposal to shareholders, which is now valued at £46 billion pounds. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire,_takeda_move_closer_to_merger_deal_1233173Shire is reportedly making a move on Swiss biotech giant Actelion, according to UK newspaper The Sunday Times. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire_offers_12bn-plus_for_actelion_971484MSD has pulled back its application to market Keytruda (pembrolizumab) in the European Union in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/msd_pulls_eu_filing_for_keytruda_combo_1209845Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/janssens_tremfya_backed_for_nhs_use_1235174
